Literature DB >> 17143327

The sticky truth about angiogenesis and thrombospondins.

Judith A Varner1.   

Abstract

The formation of new blood vessels, a process known as angiogenesis, is important for embryonic development and wound healing as well as the development of cancer and inflammation; therefore, angiogenesis is a valuable target for clinical intervention. Both logic and empiricism suggest that a balance of stimulatory and inhibitory switches is required for orderly formation of blood vessels. Thrombospondins 1 and 2 were among the first natural angiogenesis inhibitors to be identified. However, the cellular origins and mechanisms of action of these important proteins during angiogenesis have remained largely unknown. Studies by Kopp et al., presented in this issue of the JCI, clarify some of these issues by revealing that megakaryocytes and their "sticky" wound-healing progeny, platelets, are important sources of thrombospondins 1 and 2 and that these thrombopoietic cells play key roles in controlling blood vessel formation during hematopoiesis and ischemic wound healing (see the related article beginning on page 3277).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17143327      PMCID: PMC1678819          DOI: 10.1172/JCI30685

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

1.  Isolation and characterization of a high molecular weight glycoprotein from human blood platelets.

Authors:  J W Lawler; H S Slayter; J E Coligan
Journal:  J Biol Chem       Date:  1978-12-10       Impact factor: 5.157

Review 2.  Thrombospondins 1 and 2 function as inhibitors of angiogenesis.

Authors:  Lucas C Armstrong; Paul Bornstein
Journal:  Matrix Biol       Date:  2003-03       Impact factor: 11.583

3.  Thrombospondin-1 inhibits in vitro megakaryocytopoiesis via CD36.

Authors:  Mo Yang; Karen Li; Margaret Heung Ling Ng; Patrick Man Pan Yuen; Tai Fai Fok; Chi Kong Li; Philip J Hogg; Beng H Chong
Journal:  Thromb Res       Date:  2003-01-01       Impact factor: 3.944

4.  Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1.

Authors:  B Jiménez; O V Volpert; S E Crawford; M Febbraio; R L Silverstein; N Bouck
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

5.  Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice.

Authors:  M Streit; P Velasco; L Riccardi; L Spencer; L F Brown; L Janes; B Lange-Asschenfeldt; K Yano; T Hawighorst; L Iruela-Arispe; M Detmar
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

6.  Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction.

Authors:  Sara Weis; Satoshi Shintani; Alberto Weber; Rudolf Kirchmair; Malcolm Wood; Adrianna Cravens; Heather McSharry; Atsushi Iwakura; Young-Sup Yoon; Nathan Himes; Deborah Burstein; John Doukas; Richard Soll; Douglas Losordo; David Cheresh
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

7.  Thrombospondin-1-deficient mice exhibit increased vascular density during retinal vascular development and are less sensitive to hyperoxia-mediated vessel obliteration.

Authors:  Shoujian Wang; Zhifeng Wu; Christine M Sorenson; Jack Lawler; Nader Sheibani
Journal:  Dev Dyn       Date:  2003-12       Impact factor: 3.780

8.  Synthesis and secretion of thrombospondin by cultured human endothelial cells.

Authors:  D F Mosher; M J Doyle; E A Jaffe
Journal:  J Cell Biol       Date:  1982-05       Impact factor: 10.539

9.  Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis.

Authors:  Sara Weis; Jianhua Cui; Leo Barnes; David Cheresh
Journal:  J Cell Biol       Date:  2004-10-25       Impact factor: 10.539

10.  Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization.

Authors:  Hans-Georg Kopp; Andrea T Hooper; M Johan Broekman; Scott T Avecilla; Isabelle Petit; Min Luo; Till Milde; Carlos A Ramos; Fan Zhang; Tabitha Kopp; Paul Bornstein; David K Jin; Aaron J Marcus; Shahin Rafii
Journal:  J Clin Invest       Date:  2006-12       Impact factor: 14.808

View more
  3 in total

Review 1.  Megakaryocytes, malignancy and bone marrow vascular niches.

Authors:  B Psaila; D Lyden; I Roberts
Journal:  J Thromb Haemost       Date:  2012-02       Impact factor: 5.824

Review 2.  Integrins in angiogenesis and lymphangiogenesis.

Authors:  Christie J Avraamides; Barbara Garmy-Susini; Judith A Varner
Journal:  Nat Rev Cancer       Date:  2008-05-22       Impact factor: 60.716

Review 3.  The extracellular matrix and blood vessel formation: not just a scaffold.

Authors:  John M Rhodes; Michael Simons
Journal:  J Cell Mol Med       Date:  2007 Mar-Apr       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.